Therapeutic implications of the drug lag.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004232:Diuretics / Q000627:therapeutic use; D004341:Drug Evaluation; D004345:Drug Industry; D064420:Drug-Related Side Effects and Adverse Reactions; D006213:Hallucinogens / Q000627:therapeutic use; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007885:Legislation, Pharmacy; D011188:Potassium / Q000627:therapeutic use; D014116:Toxicology; D014315:Triterpenes / Q000627:therapeutic use; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D001993:Bronchodilator Agents; D004232:Diuretics; D006213:Hallucinogens; D006993:Hypnotics and Sedatives; D000960:Hypolipidemic Agents; D014315:Triterpenes; D011188:Potassium